- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Suven Life Sciences Limited reported its financial results for the quarter and nine months ended December 31, 2024. The consolidated total income stood at ₹1,466.32 crore with a net loss of ₹3,911.66 crore. Operating expenses increased, notably in R&D and employee benefits, impacting profitability. The company continues to utilize funds from its prior rights issue effectively, with notable capital allocation towards research and clinical trials. This outcome suggests a continued focus on strategic R&D investments, although significant net losses may temper investor sentiment. A potential risk lies in the mounting expenditures relative to revenue growth.